Ultragenyx Historical Cash Flow

RARE Stock  USD 46.89  1.97  4.03%   
Analysis of Ultragenyx cash flow over time is an excellent tool to project Ultragenyx future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 27.3 M or Capital Expenditures of 30.5 M as it is a great indicator of Ultragenyx ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Ultragenyx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ultragenyx is a good buy for the upcoming year.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.

About Ultragenyx Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Ultragenyx balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Ultragenyx's non-liquid assets can be easily converted into cash.

Ultragenyx Cash Flow Chart

At present, Ultragenyx's Stock Based Compensation is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 187.1 M, whereas Change In Working Capital is projected to grow to (14.3 M).

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Ultragenyx to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Ultragenyx operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most accounts from Ultragenyx's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Ultragenyx current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.At present, Ultragenyx's Stock Based Compensation is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 187.1 M, whereas Change In Working Capital is projected to grow to (14.3 M).

Ultragenyx cash flow statement Correlations

-0.070.150.44-0.46-0.02-0.32-0.370.170.42-0.070.580.090.30.140.87-0.170.460.180.370.00.00.57
-0.07-0.970.00.590.930.290.69-0.940.51-0.68-0.36-0.880.230.56-0.360.79-0.140.440.650.92-0.23-0.62
0.15-0.970.14-0.53-0.9-0.32-0.710.98-0.380.790.450.92-0.24-0.560.43-0.790.18-0.49-0.55-0.880.420.72
0.440.00.140.01-0.060.490.280.050.410.410.40.0-0.3-0.180.510.010.550.070.54-0.070.540.38
-0.460.59-0.530.010.430.320.65-0.510.610.0-0.14-0.34-0.23-0.01-0.450.34-0.520.00.180.60.33-0.31
-0.020.93-0.9-0.060.430.140.55-0.830.38-0.68-0.36-0.880.230.69-0.370.82-0.180.270.70.86-0.23-0.63
-0.320.29-0.320.490.320.140.82-0.410.060.03-0.15-0.47-0.53-0.28-0.180.280.040.160.270.20.04-0.29
-0.370.69-0.710.280.650.550.82-0.780.33-0.31-0.37-0.75-0.30.14-0.430.67-0.160.340.510.55-0.08-0.61
0.17-0.940.980.05-0.51-0.83-0.41-0.78-0.330.770.510.9-0.24-0.550.45-0.830.06-0.62-0.58-0.80.430.76
0.420.51-0.380.410.610.380.060.33-0.33-0.010.4-0.230.00.080.350.14-0.120.130.480.580.370.23
-0.07-0.680.790.410.0-0.680.03-0.310.77-0.010.480.75-0.52-0.670.27-0.670.0-0.63-0.37-0.560.840.68
0.58-0.360.450.4-0.14-0.36-0.15-0.370.510.40.480.41-0.44-0.440.77-0.610.04-0.41-0.11-0.180.480.82
0.09-0.880.920.0-0.34-0.88-0.47-0.750.9-0.230.750.41-0.06-0.510.35-0.810.13-0.38-0.64-0.760.460.71
0.30.23-0.24-0.3-0.230.23-0.53-0.3-0.240.0-0.52-0.44-0.060.570.020.240.340.570.160.19-0.44-0.16
0.140.56-0.56-0.18-0.010.69-0.280.14-0.550.08-0.67-0.44-0.510.57-0.310.770.130.480.630.43-0.36-0.58
0.87-0.360.430.51-0.45-0.37-0.18-0.430.450.350.270.770.350.02-0.31-0.540.38-0.070.05-0.230.180.84
-0.170.79-0.790.010.340.820.280.67-0.830.14-0.67-0.61-0.810.240.77-0.540.020.560.770.59-0.34-0.85
0.46-0.140.180.55-0.52-0.180.04-0.160.06-0.120.00.040.130.340.130.380.020.460.28-0.340.00.17
0.180.44-0.490.070.00.270.160.34-0.620.13-0.63-0.41-0.380.570.48-0.070.560.460.440.27-0.53-0.44
0.370.65-0.550.540.180.70.270.51-0.580.48-0.37-0.11-0.640.160.630.050.770.280.440.530.01-0.32
0.00.92-0.88-0.070.60.860.20.55-0.80.58-0.56-0.18-0.760.190.43-0.230.59-0.340.270.53-0.14-0.41
0.0-0.230.420.540.33-0.230.04-0.080.430.370.840.480.46-0.44-0.360.18-0.340.0-0.530.01-0.140.53
0.57-0.620.720.38-0.31-0.63-0.29-0.610.760.230.680.820.71-0.16-0.580.84-0.850.17-0.44-0.32-0.410.53
Click cells to compare fundamentals

Ultragenyx Account Relationship Matchups

Ultragenyx cash flow statement Accounts

201920202021202220232024 (projected)
Change In Cash320.7M290.1M(416.7M)(172.0M)81.8M85.9M
Stock Based Compensation82.0M85.7M105.0M130.4M135.2M142.0M
Free Cash Flow(370.2M)(176.1M)(411.8M)(526.6M)(521.6M)(495.5M)
Change In Working Capital(15.9M)104.7M(63.2M)60.2M(15.1M)(14.3M)
Begin Period Cash Flow115.5M436.2M726.3M309.6M137.6M187.1M
Other Cashflows From Financing Activities679.3M89.1M39.6M501.2M8.4M8.0M
Depreciation8.5M12.3M13.2M18.2M26.0M27.3M
Other Non Cash Items1.7M21.5M11.7M119.8M(12.7M)(12.0M)
Capital Expenditures24.8M43.9M73.1M146.1M46.8M30.5M
Total Cash From Operating Activities(345.4M)(132.2M)(338.7M)(380.5M)(474.8M)(451.1M)
Net Income(402.7M)(186.6M)(454.0M)(707.4M)(606.6M)(576.3M)
Total Cash From Financing Activities679.3M600.3M118.6M501.2M388.1M309.6M
End Period Cash Flow436.2M726.3M309.6M137.6M219.4M205.5M
Change To Account Receivables(20.1M)9.8M(5.4M)(12.1M)(22.8M)(21.6M)
Other Cashflows From Investing Activities11.8M74.3M78.9M(95.8M)(110.1M)(104.6M)
Sale Purchase Of Stock340.2M524.8M40.1M10.8M9.7M9.2M
Change To Inventory(4.5M)(1.3M)(3.1M)(9.7M)(6.9M)(6.6M)
Investments11.8M(209.5M)(201.2M)(291.7M)103.4M108.6M
Total Cashflows From Investing Activities(13.0M)(179.1M)(195.4M)(291.7M)(262.5M)(249.4M)
Cash And Cash Equivalents Changes320.9M288.9M(415.5M)(170.9M)(153.8M)(146.1M)
Cash Flows Other Operating(3.7M)31.8M103.8M253.0M291.0M305.5M
Change To Operating Activities(6.8M)2.7M(29.5M)3.8M3.4M3.6M
Change To Netincome83.2M946K235K74.8M86.0M90.3M
Change To Liabilities15.5M93.4M(25.2M)78.2M89.9M94.4M
Change Receivables(20.1M)9.8M(5.4M)(12.1M)(13.9M)(14.6M)
Issuance Of Capital Stock355.2M511.2M78.9M28.5M53.3M50.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.35)
Revenue Per Share
6.015
Quarterly Revenue Growth
0.423
Return On Assets
(0.24)
Return On Equity
(2.90)
The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.